Targeted Therapy in Ovarian Cancer

Table 2

Review of studies of antiangiogenic agents in recurrent or persistent ovarian cancer. RR: response rate, HTN: hypertension, RF: renal failure, P/S: platinum-sensitive, P/R: platinum resistant. *2 confirmed and one unconfirmed partial response. ^**1 unconfirmed partial response.

Agent	Authors	RR	Toxicities
VEGF trap	Tew et al.	5/45 partial	HTN, proteinuria, encephalopathy, RF
Cediranib	Hirte et al.	P/S: 3/17 partial*	Diarrhea, HTN, fatigue, anorexia
		P/R: 1/24 partial^**